Michael Webster-Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Webster-Clark has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Til Stürmer
Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
9 shared publications - Robert William Platt
Department of Epidemiology, Biostatistics, and Occupational Health McGill University Montreal Quebec Canada
7 shared publications - Jennifer L. Lund
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
6 shared publications - Sengwee Toh
Harvard Pilgrim Health Care Institute Department of Population Medicine Boston, MA 02215
4 shared publications - Anna María Nápoles
Division of Intramural Research, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, USA
3 shared publications - Bradford E. Jackson
University of North Carolina at Chapel Hill 2 Chapel Hill
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (4)
Transporting Lung Cancer Screening Effects From National Lung Screening Trial to a US Screening-Eligible Population
Purpose: The National Lung Screening Trial (NLST) found that screening with annual low-dose computed tomography (LDCT) reduces lung cancer (LC) mortality. Because studies have shown that the US population eligible for screening differs from NLST, we sought to quantitatively extend the NLST findings to this population. Methods: We reweighted individual-level NLST data using inverse odds weights (IOW) to the covariate distribution of a contemporary screening-eligible population from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) data. In the IOW and unweighted NLST population, we estimated the LC-specific and all-cause mortality among individuals undergoing three annual screenings of LDCT compared with chest radiography, as well as false-positive rates in the LDCT arm only. Results: We included 53,454 NLST participants and 7,265,314 survey-weighted screening-eligible BRFSS respondents (unweighted sample of 15,779). The BRFSS population was older, more racially and ethnically diverse, and more likely to currently smoke and have respiratory comorbidities. We estimated similar benefits of screening on LC and all-cause mortality in the weighted versus unweighted NLST population (5-year LC risk difference [RD; 95% CI], –29 [–54, 4] v –23 [–44, 3]; all-cause RD [95% CI], –44 [–95, 8] v –37 [–66, –7] deaths per 10,000 screened). Estimated false-positive rates were higher in the weighted versus unweighted NLST population across three annual screenings. Conclusion: We estimated similar mortality benefits and slightly increased false-positive rates from LDCT in the weighted versus unweighted NLST population. Our findings account for the potential differences within subgroups of interest but not variations in longitudinal adherence and diagnostic work-up between trial and clinical practice.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (4)
Open AccessTransporting Lung Cancer Screening Effects From National Lung Screening Trial to a US Screening-Eligible Population
Purpose: The National Lung Screening Trial (NLST) found that screening with annual low-dose computed tomography (LDCT) reduces lung cancer (LC) mortality. Because studies have shown that the US population eligible for screening differs from NLST, we sought to quantitatively extend the NLST findings to this population. Methods: We reweighted individual-level NLST data using inverse odds weights (IOW) to the covariate distribution of a contemporary screening-eligible population from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) data. In the IOW and unweighted NLST population, we estimated the LC-specific and all-cause mortality among individuals undergoing three annual screenings of LDCT compared with chest radiography, as well as false-positive rates in the LDCT arm only. Results: We included 53,454 NLST participants and 7,265,314 survey-weighted screening-eligible BRFSS respondents (unweighted sample of 15,779). The BRFSS population was older, more racially and ethnically diverse, and more likely to currently smoke and have respiratory comorbidities. We estimated similar benefits of screening on LC and all-cause mortality in the weighted versus unweighted NLST population (5-year LC risk difference [RD; 95% CI], –29 [–54, 4] v –23 [–44, 3]; all-cause RD [95% CI], –44 [–95, 8] v –37 [–66, –7] deaths per 10,000 screened). Estimated false-positive rates were higher in the weighted versus unweighted NLST population across three annual screenings. Conclusion: We estimated similar mortality benefits and slightly increased false-positive rates from LDCT in the weighted versus unweighted NLST population. Our findings account for the potential differences within subgroups of interest but not variations in longitudinal adherence and diagnostic work-up between trial and clinical practice.
- Open Access
Obesity in the GLP-1 Era: Clinical Characteristics and Prescribing Patterns in a Large Integrated Health System
Structured Aims: To characterize adults with obesity in a large integrated health system. Methods: We created a cross-sectional cohort of adults with at least one body mass index (BMI) value >=30 kg/m2 in the prior 18 months, a recent in-person outpatient visit, and an assigned primary care provider. Electronic health record data were transformed into a patient-level analytic dataset and linked to neighborhood-level social determinants of health. Diagnoses, laboratory values, vital signs, and prescriptions were curated using reproducible phenotype definitions and internally reviewed vocabularies. Results: The registry included 280,186 adults, of whom 48% had class I obesity. The cohort was 63% female, 27% Black, and 14% lived in areas with high or very high deprivation. Common comorbidities included hypertension, type 2 diabetes, depression, and anxiety. HbA1c and cholesterol measurements were absent in more than 40% of the cohort during the prior two years. Overall, 22% of patients received a prescription for at least one weight loss drug in the past 2 years, including 18% who received a weight-loss-approved GLP-1 receptor agonist. Conclusions: This care-engaged obesity cohort was characterized by high representation of women and socially vulnerable populations, substantial cardiometabolic screening gaps, and broad adoption of GLP-1 agonists.
Open AccessObesity in the GLP-1 Era: Clinical Characteristics and Prescribing Patterns in a Large Integrated Health System
Structured Aims: To characterize adults with obesity in a large integrated health system. Methods: We created a cross-sectional cohort of adults with at least one body mass index (BMI) value >=30 kg/m2 in the prior 18 months, a recent in-person outpatient visit, and an assigned primary care provider. Electronic health record data were transformed into a patient-level analytic dataset and linked to neighborhood-level social determinants of health. Diagnoses, laboratory values, vital signs, and prescriptions were curated using reproducible phenotype definitions and internally reviewed vocabularies. Results: The registry included 280,186 adults, of whom 48% had class I obesity. The cohort was 63% female, 27% Black, and 14% lived in areas with high or very high deprivation. Common comorbidities included hypertension, type 2 diabetes, depression, and anxiety. HbA1c and cholesterol measurements were absent in more than 40% of the cohort during the prior two years. Overall, 22% of patients received a prescription for at least one weight loss drug in the past 2 years, including 18% who received a weight-loss-approved GLP-1 receptor agonist. Conclusions: This care-engaged obesity cohort was characterized by high representation of women and socially vulnerable populations, substantial cardiometabolic screening gaps, and broad adoption of GLP-1 agonists.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
Background:Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are.Methods:To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known.Results:24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates.Conclusions:Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present.Impact:Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
Background:Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are.Methods:To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known.Results:24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates.Conclusions:Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present.Impact:Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
Supplementary Figure from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
Supplementary Figure from The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
- Open Access
- 12 October 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (10) , e70235
Comparing IPCW Models to Adjust for Informative Censoring During COVID ‐19 Using Data From the Clinical Practice Research Datalink
Purpose: Observational comparative studies can be analyzed using intention‐to‐treat (ITT) (i.e., initial‐treatment) or as‐treated (AT) (i.e., per‐protocol) approaches to estimate distinct treatment effects. Unfortunately, AT analyses have an increased vulnerability to selection bias from informative censoring. While methods for informative censoring adjustment are well established, the nuances of their implementation are less well documented. Methods: We compared marginal hazard ratios for all‐cause mortality from ITT and AT analyses comparing new users of selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) in the clinical practice research datalink from 2019 to 2022 using inverse probability of treatment weights. We created inverse probability of censoring weights (IPCW) using (A) non‐lagged and (B) lagged models to adjust for informative censoring in the AT analyses. We replicated analyses comparing acetylcholinesterase inhibitor and angiotensin receptor blocker initiators to assess the impact of IPCW in a different context. Results: We identified 335 469 SSRI initiators and 24 318 SNRI initiators. While AT estimates (HR: 1.50, 95% CI: 1.30–1.74) were further from the null than ITT estimates (HR: 1.22, 95% CI: 1.12–1.32), applying IPCW attenuated AT estimates using both lagged and non‐lagged models (lagged HR: 1.24, 95% CI: 1.08–1.44; non‐lagged HR: 1.16, 95% CI: 1.00–1.33). In the 337 981 antihypertensive initiators, however, IPCW did not influence AT estimates. Conclusions: Younger patients were more likely to discontinue SSRIs than SNRIs, resulting in biased AT estimates closer to estimates in older patients. IPCW attenuated this bias, highlighting the utility of weighting when censoring is linked to patient characteristics.
- 12 October 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (10) , e70235
Open AccessComparing IPCW Models to Adjust for Informative Censoring During COVID ‐19 Using Data From the Clinical Practice Research Datalink
Purpose: Observational comparative studies can be analyzed using intention‐to‐treat (ITT) (i.e., initial‐treatment) or as‐treated (AT) (i.e., per‐protocol) approaches to estimate distinct treatment effects. Unfortunately, AT analyses have an increased vulnerability to selection bias from informative censoring. While methods for informative censoring adjustment are well established, the nuances of their implementation are less well documented. Methods: We compared marginal hazard ratios for all‐cause mortality from ITT and AT analyses comparing new users of selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) in the clinical practice research datalink from 2019 to 2022 using inverse probability of treatment weights. We created inverse probability of censoring weights (IPCW) using (A) non‐lagged and (B) lagged models to adjust for informative censoring in the AT analyses. We replicated analyses comparing acetylcholinesterase inhibitor and angiotensin receptor blocker initiators to assess the impact of IPCW in a different context. Results: We identified 335 469 SSRI initiators and 24 318 SNRI initiators. While AT estimates (HR: 1.50, 95% CI: 1.30–1.74) were further from the null than ITT estimates (HR: 1.22, 95% CI: 1.12–1.32), applying IPCW attenuated AT estimates using both lagged and non‐lagged models (lagged HR: 1.24, 95% CI: 1.08–1.44; non‐lagged HR: 1.16, 95% CI: 1.00–1.33). In the 337 981 antihypertensive initiators, however, IPCW did not influence AT estimates. Conclusions: Younger patients were more likely to discontinue SSRIs than SNRIs, resulting in biased AT estimates closer to estimates in older patients. IPCW attenuated this bias, highlighting the utility of weighting when censoring is linked to patient characteristics.
- 22 September 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 231-233
Considerations When Generalising Using Survey Sampling Weights
- 22 September 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 231-233
Considerations When Generalising Using Survey Sampling Weights
- 4 August 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (11) , 6178-6187
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study
Aims: To evaluate the risk of incident suicidal ideation (SI) and suicidality (SI , suicide attempt or intentional self‐harm) among overweight or obese adults who were prescribed semaglutide for weight management compared with active comparators (weight management drugs: bupropion/naltrexone, orlistat, phentermine or phentermine/topiramate ). Materials and Methods: Using the Merative® MarketScan Databases, we conducted a retrospective cohort study of adults initiating semaglutide or an active comparator between 01 June 2021, and 31 December 2022. Patients were required to have ≥1 year of continuous health and pharmacy plan coverage, a diagnosis of overweight or obesity, no prior suicidality or type 2 diabetes, and new users of semaglutide or active comparators for inclusion. SI and suicidality were identified using diagnosis codes within 183 days of drug initiation. Kaplan–Meier analysis was used to estimate risks, risk differences (RDs), and risk ratios (RRs), controlling for confounding with standardized mortality ratio weights. Results: Among 16 822 semaglutide and 11 986 active comparator new users, the adjusted risk of incident SI was 0.08% (13.0 events) for semaglutide and 0.05% (8.9 events) for active comparators, and for incident suicidality was 0.08% (14.0 events) for semaglutide and 0.07% (11.0 events) for active comparators. Adjusted RDs were 0.02% (95% CI: [−0.02%, 0.07%]) for SI and 0.02% (−0.03%, 0.07%) for suicidality, with corresponding RRs of 1.36 (0.62, 6.14) and 1.18 (0.57, 3.63). Conclusion: Among patients initiating semaglutide for weight management, semaglutide did not appear to increase the risk of suicide‐related outcomes. However, the CIs of the RDs are compatible with a 0.07% increase in 6‐month risk and the true RD could be larger due to the potentially low sensitivity of ICD‐10 diagnosis codes for and underreporting of suicide‐related outcomes. Additional studies are critical to confirm these findings and obtain more precise estimates of any potential benefits or harms of semaglutide.
- 4 August 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (11) , 6178-6187
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study
Aims: To evaluate the risk of incident suicidal ideation (SI) and suicidality (SI , suicide attempt or intentional self‐harm) among overweight or obese adults who were prescribed semaglutide for weight management compared with active comparators (weight management drugs: bupropion/naltrexone, orlistat, phentermine or phentermine/topiramate ). Materials and Methods: Using the Merative® MarketScan Databases, we conducted a retrospective cohort study of adults initiating semaglutide or an active comparator between 01 June 2021, and 31 December 2022. Patients were required to have ≥1 year of continuous health and pharmacy plan coverage, a diagnosis of overweight or obesity, no prior suicidality or type 2 diabetes, and new users of semaglutide or active comparators for inclusion. SI and suicidality were identified using diagnosis codes within 183 days of drug initiation. Kaplan–Meier analysis was used to estimate risks, risk differences (RDs), and risk ratios (RRs), controlling for confounding with standardized mortality ratio weights. Results: Among 16 822 semaglutide and 11 986 active comparator new users, the adjusted risk of incident SI was 0.08% (13.0 events) for semaglutide and 0.05% (8.9 events) for active comparators, and for incident suicidality was 0.08% (14.0 events) for semaglutide and 0.07% (11.0 events) for active comparators. Adjusted RDs were 0.02% (95% CI: [−0.02%, 0.07%]) for SI and 0.02% (−0.03%, 0.07%) for suicidality, with corresponding RRs of 1.36 (0.62, 6.14) and 1.18 (0.57, 3.63). Conclusion: Among patients initiating semaglutide for weight management, semaglutide did not appear to increase the risk of suicide‐related outcomes. However, the CIs of the RDs are compatible with a 0.07% increase in 6‐month risk and the true RD could be larger due to the potentially low sensitivity of ICD‐10 diagnosis codes for and underreporting of suicide‐related outcomes. Additional studies are critical to confirm these findings and obtain more precise estimates of any potential benefits or harms of semaglutide.
- Open Access
- 7 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111716
Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses
- 7 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111716
Open AccessUsing methods to extend inferences to specific target populations to improve the precision of subgroup analyses
- Open Access
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (8) , 1176-1181
Variable selection when estimating effects in external target populations
External validity is an important part of epidemiologic research. To validly estimate effects in specific external target populations using a chosen effect measure (ie, “transport”), some methods require that one account for all effect measure modifiers (EMMs). However, little is known about how including other variables that are not EMMs (ie, non-EMMs) in adjustment sets affects estimates. Using simulations, we evaluated how inclusion of non-EMMs affected estimation of the transported risk difference (RD) by assessing the impacts of covariates that (1) differ (or not) between the trial and the target, (2) are associated with the outcome (or not), and (3) modify the RD (or not). We assessed variation and bias when covariates with each possible combination of these factors were used to transport RDs using outcome modeling or inverse odds weighting. Inclusion of variables that differed in distribution between the populations but were non-EMMs reduced precision, regardless of whether they were associated with the outcome. However, non-EMMs associated with selection did not amplify bias resulting from omission of necessary EMMs. Including all variables associated with the outcome may result in unnecessarily imprecise estimates when estimating treatment effects in external target populations.
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (8) , 1176-1181
Open AccessVariable selection when estimating effects in external target populations
External validity is an important part of epidemiologic research. To validly estimate effects in specific external target populations using a chosen effect measure (ie, “transport”), some methods require that one account for all effect measure modifiers (EMMs). However, little is known about how including other variables that are not EMMs (ie, non-EMMs) in adjustment sets affects estimates. Using simulations, we evaluated how inclusion of non-EMMs affected estimation of the transported risk difference (RD) by assessing the impacts of covariates that (1) differ (or not) between the trial and the target, (2) are associated with the outcome (or not), and (3) modify the RD (or not). We assessed variation and bias when covariates with each possible combination of these factors were used to transport RDs using outcome modeling or inverse odds weighting. Inclusion of variables that differed in distribution between the populations but were non-EMMs reduced precision, regardless of whether they were associated with the outcome. However, non-EMMs associated with selection did not amplify bias resulting from omission of necessary EMMs. Including all variables associated with the outcome may result in unnecessarily imprecise estimates when estimating treatment effects in external target populations.
- Open Access
- 4 April 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (4) , e5790
Clarifying the causal contrast: An empirical example applying the prevalent new user study design
Purpose: The prevalent new user design extends the active comparator new user design to include patients switching to a treatment of interest from a comparator. We examined the impact of adding “switchers” to incident new users on the estimated hazard ratio (HR) of hospitalized heart failure.Methods: Using MarketScan claims data (2000–2014), we estimated HRs of hospitalized heart failure between patients initiating GLP‐1 receptor agonists (GLP‐1 RA) and sulfonylureas (SU). We considered three estimands: (1) the effect of incident new use; (2) the effect of switching; and (3) the effect of incident new use or switching, combining the two population. We used time‐conditional propensity scores (TCPS) and time‐stratified standardized morbidity ratio (SMR) weighting to adjust for confounding.Results: We identified 76 179 GLP‐1 RA new users, of which 12% were direct switchers (within 30 days) from SU. Among incident new users, GLP‐1 RA was protective against heart failure (adjHRSMR = 0.74 [0.69, 0.80]). Among switchers, GLP‐1 RA was not protective (adjHRSMR = 0.99 [0.83, 1.18]). Results in the combined population were largely driven by the incident new users, with GLP‐1 RA having a protective effect (adjHRSMR = 0.77 [0.72, 0.83]). Results using TCPS were consistent with those estimated using SMR weighting.Conclusions: When analyses were conducted only among incident new users, GLP‐1 RA had a protective effect. However, among switchers from SU to GLP‐1 RA, the effect estimates substantially shifted toward the null. Combining patients with varying treatment histories can result in poor confounding control and camouflage important heterogeneity.
- 4 April 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (4) , e5790
Open AccessClarifying the causal contrast: An empirical example applying the prevalent new user study design
Purpose: The prevalent new user design extends the active comparator new user design to include patients switching to a treatment of interest from a comparator. We examined the impact of adding “switchers” to incident new users on the estimated hazard ratio (HR) of hospitalized heart failure.Methods: Using MarketScan claims data (2000–2014), we estimated HRs of hospitalized heart failure between patients initiating GLP‐1 receptor agonists (GLP‐1 RA) and sulfonylureas (SU). We considered three estimands: (1) the effect of incident new use; (2) the effect of switching; and (3) the effect of incident new use or switching, combining the two population. We used time‐conditional propensity scores (TCPS) and time‐stratified standardized morbidity ratio (SMR) weighting to adjust for confounding.Results: We identified 76 179 GLP‐1 RA new users, of which 12% were direct switchers (within 30 days) from SU. Among incident new users, GLP‐1 RA was protective against heart failure (adjHRSMR = 0.74 [0.69, 0.80]). Among switchers, GLP‐1 RA was not protective (adjHRSMR = 0.99 [0.83, 1.18]). Results in the combined population were largely driven by the incident new users, with GLP‐1 RA having a protective effect (adjHRSMR = 0.77 [0.72, 0.83]). Results using TCPS were consistent with those estimated using SMR weighting.Conclusions: When analyses were conducted only among incident new users, GLP‐1 RA had a protective effect. However, among switchers from SU to GLP‐1 RA, the effect estimates substantially shifted toward the null. Combining patients with varying treatment histories can result in poor confounding control and camouflage important heterogeneity.